Age (years; mean, SD) |
64.8 (12.3) |
66.8 (12.0) (p < 0.01) |
65.4 (12.2) |
|
Gender- Male (n,%) |
542 (65.5%) |
286 (34.5%) |
828 (50.6%) |
|
Female (n,%) |
549 (67.9%) |
259 (32.1%) (p=NS) |
808 (49.4%) |
|
BMI (kg/m2; mean, SD) |
33.5 (7.5) |
32.7 (7.8) (p < 0.05) |
33.2 (7.6) |
|
Normal (n,%) |
118 (59.9%) |
79 (40.1%) |
197 (11.9%) |
|
Overweight (n,%) |
276 (66.2%) |
141 (33.8%) |
417 (25.2%) |
|
Obese (n,%) |
521 (68.1%) |
244 (31.9%) |
765 (46.2%) |
|
Morbidly obese (n,%) |
190 (68.6%) |
87 (31.4%) |
277 (16.7%) |
|
Racial/ethnic background (n,%) |
|
(p < 0.001) |
|
|
Caucasian |
452 (60.6%) |
294 (39.4%) |
746 (45.0%) |
|
African-American |
211 (78.7%) |
57 (21.3%) |
268 (16.2%) |
|
Hispanic |
112 (71.8%) |
44 (28.2%) |
156 (9.4%) |
|
Unknown/not documented |
330 (67.9%) |
156 (32.1%) |
486 (29.3%) |
|
Prescribed lifestyle modifications to control BP (%) |
706 (64.8%) |
353 (65.0%) |
1059(64.8%) |
|
Number of antihypertensive medications (mean, SD) |
2.2 (1.2) |
2.3 (1.2) (p=NS) |
2.3 (1.2) |
|
Number of chronic medications (mean, SD) |
7.1 (3.6) |
8.1 (4.0) (p < 0.001) |
7.4 (3.8) |
|
Antihypertensive medication class |
Use among uncontrolled patients (n = 1,105) |
Use among controlled patients (n = 551) |
Use among all patients (n = 1,656) |
|
ACEI/ARB |
75.7% |
81.7% (p < 0.02) |
78.3% |
|
BB |
39.7% |
43.6% (p=NS) |
41.0% |
|
CCB |
33.4% |
26.1% (p < 0.01) |
31.0% |
|
Any diuretic |
50.6% |
55.4% (p=NS) |
52.2% |
|
|
% with BP control among patients with condition |
% with BP control among patients without condition |
|
|
Hyperlipidemia (%) |
35.1% |
27.8% (p = 0.006) |
|
|
Renal disease/insufficiency (%) |
46.7% |
31.4% (p < 0.001) |
|
|
CAD without MI (%) |
38.4% |
32.1% (p < 0.04) |
|
|
ACEI and/or ARB use (%) |
34.7% |
28.1% (p < 0.03) |
|